NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

主要7個國家的地圖狀萎縮 (GA) 市場:市場分析、流行病學、成長預測 (∼2030年)

Geographic Atrophy (GA) Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 945499
出版日期 按訂單生產 內容資訊 英文 200 Pages
商品交期: 10個工作天內
價格
主要7個國家的地圖狀萎縮 (GA) 市場:市場分析、流行病學、成長預測 (∼2030年) Geographic Atrophy (GA) Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 200 Pages
簡介

全球主要7個國家 (美國、英國、德國、法國、義大利、西班牙、日本) 的地圖狀萎縮 (GA)的2017年的患病數為272萬6453人,同年的市場規模估計為2億7600萬美元。各地區、國家中,美國的市場規模最大,同年的市場規模記錄1億8100萬美元。還有歐盟5國的市場規模記錄8300萬美元,日本市場規模為1200萬美元。

本報告提供主要7個國家地圖狀萎縮 (GA)的市場調查,疾病的背景、概要,各地區、國家的罹患情形,目前治療方法,未滿足需求,新藥及臨床開發趨勢,市場規模的變化、預測,市場進入、償付趨勢,市場成長的各種影響因素分析等資訊。

第1章 重要考察

第2章 地圖狀萎縮 (GA) :概要

第3章 KOL的見解

第4章 SWOT分析

第5章 市場概要

第6章 疾病的背景、概要

  • 老年性黃斑部病變 (AMD)
  • 地圖狀萎縮 (GA)
    • GA的前兆、症狀
    • GA的風險因素
    • GA的預後因素
    • GA的病的進展
    • GA的病理生理學

第7章 GA的影像診斷

第8章 流行病學、患者人口

  • 主要的流行病學的觀察
  • 前提條件、合理性:主要7個國家
  • 流行病學的方案:主要7個國家

第9章 美國的流行病學的分析

  • 患病人數
  • 診斷患者數
  • 診斷患者數:年齡分佈
  • 患者數:各視覺障礙
  • 治療者數

第10章 歐洲5個國家的流行病學的分析

  • 患病人數
  • 診斷患者數
  • 診斷患者數:年齡分佈
  • 患者數:各視覺障礙
  • 治療者數
    • 法國
    • 義大利
    • 西班牙
    • 英國

第11章 日本的流行病學的分析

  • 患病人數
  • 診斷患者數
  • 診斷患者數:年齡分佈
  • 患者數:各視覺障礙
  • 治療者數

第12章 GA的治療

  • AMD的治療流程
  • 目前治療方法
  • 新的治療方法評估的持續研究

第13章 未滿足需求

第14章 GA患者的路程

第15章 GA的臨床試驗的主要端點

第16章 新治療方法

  • pegusetakopuran (APL-2) :Apellis Pharmaceuticals
  • Zimura (avacincaptad pegol) :Iveric Bio (舊Ophthotech Corporation)
  • ALK-001:Alkeus Pharmaceuticals
  • HMR59 (AAVCAGsCD59) :Hemera Biosciences
  • risuteganibu:Allegro Ophthalmics
  • eramipurechido:Stealth BioTherapeutics
  • GT005:Gyroscope Therapeutics
  • CPCB-RPE1:Regenerative Patch Technologies
  • RO7171009 (RG6147) :Roche (Genentech)
  • IONIS-FB-LRx:Ionis Pharmaceuticals/Roche
  • OpRegen:CellCure Neurosciences (Lineage Cell Therapeutics的子公司)
  • Palucorcel (CNTO 2476) :Janssen Research & Development

第17章 聯合分析

第18章 市場主要7個國家

  • 主要調查結果
  • 市場預測

第19章 主要7個國家的市場規模

  • 市場規模
  • 市場規模:各治療法
  • 美國市場
  • 市場歐洲5個國家
  • 日本市場規模

第20章 市場進入、償付趨勢

第21章 市場成長的促進因素

第22章 市場障礙

第23章 附錄

章24:DelveInsight的服務內容

第25章 免責聲明

第26章:關於DelveInsight

目錄
Product Code: DIMI0825

DelveInsight's "Geographic Atrophy (GA) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Geographic Atrophy (GA) , historical and forecasted epidemiology as well as the Geographic Atrophy (GA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Geographic Atrophy (GA) market report provides current treatment practices, emerging drugs, Geographic Atrophy (GA) market share of the individual therapies, current and forecasted Geographic Atrophy (GA) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Geographic Atrophy (GA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Geographic Atrophy (GA) Disease Understanding and Treatment Algorithm

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: "dry" and "wet". According to the "American Macular Degeneration Foundation," approximately 85-90% of the cases of macular degeneration are the "dry" (atrophic) type.

GA is a progressive, irreversible and blinding disease that tends to affect both eyes. Nearly two-thirds geographic atrophy cases are reported in the people aged 80 years and above. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK.

GA is characterized by one or more distinct dark patches on the retina, with corresponding areas of reduced vision or 'blind spots'. These dark patches represent the death of different cell types in the retina, including the light-sensitive photoreceptors.

Diagnosis

The development of imaging technologies has contributed to the understanding of the genesis and pathophysiological mechanisms of GA secondary to AMD. At present, to distinguish GA from other forms of dry AMD, color fundus photography and biomicroscopy FA examination are used. In addition to this, modern in vivo imaging technology, such as spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) allows for non-invasive and rapid quantitative morphological assessment of GA in the clinical setting also being used for GA.

Treatment

Currently, there are no approved treatments present for GA. The AREDS study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene and zinc could significantly reduce the risk of progressing to advanced AMD and sometimes low visual aids and counseling is also helpful. Several therapies which reached in advanced stage of development are already failed, however currently several therapies are in the pipeline to prevent the progression of GA.

Geographic Atrophy (GA) Epidemiology

The Geographic Atrophy (GA) epidemiology division provide insights about historical and current Geographic Atrophy (GA) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of GA in the 7MM were found to be 2,726,453 in 2017 which is expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted GA epidemiology [segmented as Total Prevalent Cases of GA, Total Diagnosed Cases of GA, Total Diagnosed cases of GA by Age Distribution, Total Geographic Atrophy Cases by Visual Impairment, and Total Treated Cases of GA] scenario of GA in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

Country Wise- Geographic Atrophy (GA) Epidemiology

The epidemiology segment also provides the Geographic Atrophy (GA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographic Atrophy (GA) Drug Chapters

Drug chapter segment of the Geographic Atrophy (GA) report encloses the detailed analysis of Geographic Atrophy (GA) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Geographic Atrophy (GA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Geographic Atrophy (GA) Emerging Drugs

Pegcetacoplan (APL-2): Apellis Pharmaceuticals

Pegcetacoplan (formerly known as APL-2), is under development by Apellis Pharmaceuticals. It is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b.

Currently two phase III trial is ongoing for GA secondary to age-related macular degeneration (AMD). The Phase III program in GA consists of two 600-patient prospective, multicenter, randomized, double-masked, sham-injection controlled trials to assess the efficacy and safety of multiple intravitreal injections of pegcetacoplan in patients with GA, with the goal of enrolling a total of 1,200 patients across approximately 200 sites worldwide. Company refers to these trials as the DERBY and OAKS trials. Company dosed the first patient in Phase III trials in September 2018. It is expected that both trials will be fully enrolled by the end of the first half of 2020 and anticipated announcement of data from these trials will be in mid-2021.

In July 2018, the US FDA granted fast track designation to Pegcetacoplan for GA.

In November 2014, Apellis Pharmaceuticals entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology.

Zimura (avacincaptad pegol): Iveric Bio (formerly Ophthotech Corporation)

Zimura also known as avacincaptad pegol, is under development by Iveric Bio. It is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD.

The drug is currently in Phase IIb trial for the treatment of patients with GA Secondary to Dry AMD. However, in January 2020, the Company announced the design of second Phase III clinical trial of Zimura in geographic atrophy secondary to AMD, ISEE2008. In March 18, 2020, the Company announced that due to the COVID-19 pandemic, it had decided to delay the initiation of patient enrollment in the ISEE2008 trial, which was otherwise on track to begin in March 2020. The Company continues to monitor the situation closely in the United States and abroad to determine when enrollment should begin.

The Company expected topline 18-month data from its first Phase III clinical trial evaluating Zimura for the treatment of GA secondary to AMD, OPH2003, will be available by the end of the second quarter of 2020. The primary purpose of the 18-month time point is to gather additional safety data.

In April 2020, the US FDA granted Fast Track designation to Zimura for the treatment of GA secondary to AMD.

ALK-001: Alkeus Pharmaceuticals

Alkeus' drug candidate, ALK-001, is a once-a-day oral drug candidate currently being tested for the treatment of GA, which offers a chemically modified version of the vitamin that is designed to reduce the formation of those toxic clumps. ALK-001 works by replacing the C20 hydrogen atoms of vitamin A with deuterium atoms which makes cleavage of the carbon-hydrogen bond more difficult, thereby reduces Vitamin A dimerization and lipofuscin.

The company has completed a phase I clinical study (NCT02230228) which was conducted to assess the safety and pharmacokinetics of ALK-001 in healthy volunteer. At present, a Phase III (NCT03845582; Recruiting) multicenter, randomized, double-masked, parallel-group, placebo-controlled study is ongoing to investigate the safety, pharmacokinetics, tolerability, and efficacy of ALK-001 in GA Secondary to Age-related Macular Degeneration.

In January 2011, Alkeus Pharmaceuticals and Columbia University entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerative diseases of the eye.

HMR59 (AAVCAGsCD59): Hemera Biosciences

HMR59 (HMR-1001; AAVCAGsCD59) is Hemera's one-time gene therapy that works by causing retina cells to continuously produce a soluble protein called CD59 (sCD59) that blocks the final step of the complement cascade. This drug is currently being evaluated in the US FDA approved clinical trials to treat both dry and wet AMD. Macular degeneration is felt to be caused by an over activity of an inflammation cascade called complement.

In preclinical testing, AAVCAGsCD59 injected in the vitreous of mice 14 days prior to laser CNV reduced CNV formation by ~60% and MAC formation by ~70%. Hemera Biosciences's expecting to initiate a Phase II (NCT04358471; Not yet recruiting) multi-center trial in June 30, 2020, evaluating intravitreal AAVCAGsCD59 compared to sham injection for the treatment of advanced dry AMD with GA. The one-year key findings of a Phase I dose-escalation trial of HMR59 in dry AMD have shown about a 25% reduction in the growth rate of GA.

Geographic Atrophy (GA) Market Outlook

At present, the therapeutic landscape of GA is devoid of any approved treatment, and to manage this indication, and there is a substantial unmet need for a therapy to slow its worsening. The pathophysiology of GA is poorly understood. Although correlative evidence for complement, inflammation, and GA pathology has been found in human tissues, a causative role for complement, or for inflammation in general, can be demonstrated only in appropriate preclinical models of GA.

The current standard of Care is observation, and besides high doses of antioxidant vitamin, zinc supplements are found to produce a beneficial effect in slowing the progression of d-AMD. In the absence of any treatment and because of a poor correlation between BCVA and GA lesions or progression, a multimodal imaging approach is necessary to better follow up GA patients.

Several companies tried to develop a drug for this condition, but failed. One such example is Lampalizumab (Genentech/Roche). This drug blocks a region on factor D that is an important binding site for factor B. As a result, factor B cannot be cleaved therefore inhibits the alternate complement pathway.

In September 2017, press releases from Roche and Genentech announced that two phase III clinical trials of lampalizumab (Spectri and Chroma), failed to meet their primary end point of reducing mean change in GA lesion area after 48 weeks when compared with sham treatment.

At present several pharmaceutical companies are working for the development of novel approach to treat this condition. Key players like Apellis Pharmaceuticals (Pegcetacoplan; APL-2), Alkeus Pharmaceuticals (ALK-001), Iveric bio (formerly Ophthotech Corporation; Zimura), Genentech (Roche; RO7171009; RG6147), Ionis Pharmaceuticals./ Roche (IONIS-FB-LRx), Hemera Biosciences (HMR59), Allegro Ophthalmics(Risuteganib), Stealth BioTherapeutics (Elamipretide), Janssen Research & Development (Palucorcel; CNTO 2476), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences (OpRegen), Gyroscope Therapeutics (GT005), and others.

Key Findings

The GA market size in the 7MM is expected to change during the study period 2017-2030.The therapeutic market of GA in the seven major markets was USD 276 million in 2017 which is expected to increase during study period (2017-2030). According to the estimates, the highest market size of GA is found in the United States followed by the UK and France. In case of clinical trials of emerging therapies, no active companies in this space currently focusing on Japan and also no visibility around the launch scenarios in Japan hence emerging therapies launch is not considered in Japan.

The United States Market Outlook

In 2017, the total market size of GA therapies was USD 181 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of GA therapies was USD 83 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of GA therapies in Japan was USD 12 million in 2017.

Geographic Atrophy (GA) Drugs Uptake

HMR59 (Gene Therapy) expected to generate highest market size owing to one time treatment approach, expected premium pricing and impressive early stage efficacy data.

Furthermore, there are no significant differences seen in the available efficacy results of APL-2 and Zimura; but Zimura owing to better safety profile expected to have slight edge over APL-2. So, Zimura is expected to generate second highest revenue in the total GA market.

Geographic Atrophy (GA) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Geographic Atrophy (GA) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The drugs which are in pipeline include:

  • 1. Pegcetacoplan (APL-2) (Apellis Pharmaceuticals): Phase III
  • 2. ALK-001 (Alkeus Pharmaceuticals): Phase III
  • 3. Zimura (avacincaptad pegol) [Iveric bio (formerly Ophthotech Corporation)]: Phase IIb
  • 4. RO7171009 (RG6147) [Roche (Genentech)]: Phase II
  • 5. IONIS-FB-LRx (Ionis Pharmaceuticals./Roche): Phase II
  • 6. AAVCAGsCD59 (HMR59) (Hemera Biosciences): Phase II
  • 7. Risuteganib (Allegro Ophthalmics): Phase II
  • 8. Elamipretide (Stealth BioTherapeutics): Phase II
  • 9. Palucorcel (CNTO 2476) (Janssen Research & Development): Phase II

Reimbursement Scenario in Geographic Atrophy (GA)

  • According to findings from the secondary domain, for access and reimbursement of therapies in GA; the change in the BCVA and GA lesions or progression will consider as the optimal primary efficacy measure in GA.
  • The advanced form of AMD is divided into two forms, one of them is GA and another one is Wet AMD. It is worthy to mention here that the patient pool of wet AMD and GA is in similar lines; so we can predict the similar access and reimbursement scenario for upcoming emerging GA therapies.
  • Talking about the assessment by HTA bodies for wet AMD, therapies like Eylea (Aflibercept) and Lucentis (ranibizumab injection) we have explored and have analyzed the reaction of HTA bodies in case of wet AMD. HTA assessment analysis has also provide some directions around the estimated cost of treatment and how these bodies expected to react around GA therapies due to lack of any precedence of approval or assessment in GA.
  • In the case of Eylea, in July 2013, the National Institute for Health and Care Excellence (NICE) recommended Eylea as an option for treating wet AMD.
  • In March 2013, the German HTA body IQWiG released a statement claiming that, following an assessment of the benefits of Eylea, current data was unable to prove the drug was superior to Novartis' Lucentis (ranibizumab) in the treatment of wet AMD.
  • In May 2012, Lucentis was recommended by NICE as an option for the treatment of wet AMD.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Geographic Atrophy (GA) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Geographic Atrophy (GA) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Prof. Medical Director, Department of Ophthalmology, University of Bonn, Germany Views:

  • "GA is not under diagnosed, at least not to a large extent"
  • "At present, one could speculate on the aspect that emerging drug will target a specific target population or there will be any eligibility criteria. I am not aware of any specific criteria for eligibility once an effective Tx may become available"
  • "Perhaps, complement therapy will only work in subject with genetic risk polymorphism in the complement pathway"

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Geographic Atrophy (GA) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Geographic Atrophy (GA) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Geographic Atrophy (GA) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Geographic Atrophy (GA) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Geographic Atrophy (GA) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Geographic Atrophy (GA) market

Report Highlights

  • In the coming years, Geographic Atrophy (GA) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Geographic Atrophy (GA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Geographic Atrophy (GA) . Launch of emerging therapies will significantly impact the Geographic Atrophy (GA) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Geographic Atrophy (GA)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Geographic Atrophy (GA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Geographic Atrophy (GA) Pipeline Analysis
  • Geographic Atrophy (GA) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Geographic Atrophy (GA) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Geographic Atrophy (GA) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Geographic Atrophy (GA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Geographic Atrophy (GA) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Geographic Atrophy (GA) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Geographic Atrophy (GA) market size during the forecast period (2017-2030)?
  • At what CAGR, the Geographic Atrophy (GA) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Geographic Atrophy (GA) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Geographic Atrophy (GA) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Geographic Atrophy (GA) ?
  • What is the historical Geographic Atrophy (GA) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Geographic Atrophy (GA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Geographic Atrophy (GA) ?
  • Out of all 7MM countries, which country would have the highest prevalent population of Geographic Atrophy (GA) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Geographic Atrophy (GA) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Geographic Atrophy (GA) in the USA, Europe, and Japan?
  • What are the Geographic Atrophy (GA) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Geographic Atrophy (GA) ?
  • How many therapies are developed by each company for Geographic Atrophy (GA) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Geographic Atrophy (GA) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Geographic Atrophy (GA) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Geographic Atrophy (GA) and their status?
  • What are the key designations that have been granted for the emerging therapies for Geographic Atrophy (GA) ?
  • What are the global historical and forecasted market of Geographic Atrophy (GA) ?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Geographic Atrophy (GA) market
  • To understand the future market competition in the Geographic Atrophy (GA) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Geographic Atrophy (GA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Geographic Atrophy (GA) market
  • To understand the future market competition in the Geographic Atrophy (GA) market

Table of Contents

1. Key Insights

2. Executive Summary of Geographic Atrophy (GA)

3. KOL Views

4. SWOT Analysis of Geographic Atrophy (GA)

5. Geographic Atrophy: Market Overview at a Glance

6. Geographic Atrophy: Disease Background and Overview

  • 6.1. Age-related Macular Degeneration (AMD)
    • 6.1.1. Estimating Risk of AMD Progression
    • 6.1.2. Symptoms of AMD
    • 6.1.3. Stages of AMD
  • 6.2. Geographic Atrophy (GA)
    • 6.2.1. Signs and symptoms of GA
    • 6.2.2. Risk Factors of GA
    • 6.2.3. Prognostic factors for GA
    • 6.2.4. Disease Progression of GA
    • 6.2.5. Pathophysiology of GA

7. Diagnosis/Imaging of GA

8. Epidemiology and Patient Population

  • 8.1. Epidemiology Key Findings
  • 8.2. Assumptions and Rationale: 7MM
  • 8.3. Epidemiology Scenario: 7MM
    • 8.3.1. Total Prevalent Cases of Geographic Atrophy in the 7MM
    • 8.3.2. Total Diagnosed cases of Geographic Atrophy in the 7MM
    • 8.3.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in the 7MM
    • 8.3.4. Total Geographic Atrophy Cases by Visual Impairment in the 7MM
    • 8.3.5. Treated cases of Geographic Atrophy in the 7MM

9. The United States Epidemiology

  • 9.1. Total Prevalent Cases of Geographic Atrophy in the United States
  • 9.2. Total Diagnosed cases of Geographic Atrophy in the United States
  • 9.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United States
  • 9.4. Total Geographic Atrophy Cases by Visual impairment in the United States
  • 9.5. Treated cases of Geographic Atrophy in the United States

10. EU-5 Epidemiology

  • 10.1. Germany
    • 10.1.1. Total Prevalent Cases of Geographic Atrophy in Germany
    • 10.1.2. Total Diagnosed cases of Geographic Atrophy in Germany
    • 10.1.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Germany
    • 10.1.4. Total Geographic Atrophy Cases by Visual Impairment in Germany
    • 10.1.5. Treated cases of Geographic Atrophy in Germany
  • 10.2. France
    • 10.2.1. Total Prevalent Cases of Geographic Atrophy in France
    • 10.2.2. Total Diagnosed cases of Geographic Atrophy in France
    • 10.2.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in France
    • 10.2.4. Total Geographic Atrophy Cases by Visual Impairment in France
    • 10.2.5. Treated cases of Geographic Atrophy in France
  • 10.3. Italy
    • 10.3.1. Total Prevalent Cases of Geographic Atrophy in Italy
    • 10.3.2. Total Diagnosed cases of Geographic Atrophy in Italy
    • 10.3.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Italy
    • 10.3.4. Total Geographic Atrophy Cases by Visual Impairment in Italy
    • 10.3.5. Treated cases of Geographic Atrophy in Italy
  • 10.4. Spain
    • 10.4.1. Total Prevalent Cases of Geographic Atrophy in Spain
    • 10.4.2. Total Diagnosed cases of Geographic Atrophy in Spain
    • 10.4.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Spain
    • 10.4.4. Total Geographic Atrophy Cases by Visual Impairment in Spain
    • 10.4.5. Treated cases of Geographic Atrophy in Spain
  • 10.5. The United Kingdom
    • 10.5.1. Total Prevalent Cases of Geographic Atrophy in the United Kingdom
    • 10.5.2. Total Diagnosed cases of Geographic Atrophy in the United Kingdom
    • 10.5.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United Kingdom
    • 10.5.4. Total Geographic Atrophy Cases by Visual Impairment in the United Kingdom
    • 10.5.5. Treated cases of Geographic Atrophy in the United Kingdom

11. Japan Epidemiology

  • 11.1. Total Prevalent Cases of Geographic Atrophy in Japan
  • 11.2. Total Diagnosed cases of Geographic Atrophy in Japan
  • 11.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Japan
  • 11.4. Total Geographic Atrophy Cases by Visual Impairment in Japan
  • 11.5. Treated cases of Geographic Atrophy in Japan

12. Treatment of GA

  • 12.1. Treatment Algorithm AMD
  • 12.2. Current Treatment
  • 12.3. Ongoing Research to Evaluate New Treatment Options

13. Unmet Needs

14. Patient Journey of GA

15. Key Endpoints in Geographic Atrophy (GA) Clinical Trials

16. Emerging Therapies

  • 16.1. Key Cross
  • 16.2. Pegcetacoplan (APL-2): Apellis Pharmaceuticals
    • 16.2.1. Product Description
    • 16.2.2. Other Developmental Activities
    • 16.2.3. Clinical Development
    • 16.2.4. Safety and Efficacy
  • 16.3. Zimura (avacincaptad pegol): Iveric Bio (formerly Ophthotech Corporation)
    • 16.3.1. Product Description
    • 16.3.2. Other Developmental Activities
    • 16.3.3. Clinical Development
    • 16.3.4. Safety and Efficacy
  • 16.4. ALK-001: Alkeus Pharmaceuticals
    • 16.4.1. Product Description
    • 16.4.2. Other Developmental Activities
    • 16.4.3. Clinical Development
  • 16.5. HMR59 (AAVCAGsCD59): Hemera Biosciences
    • 16.5.1. Product Description
    • 16.5.2. Other Developmental Activities
    • 16.5.3. Clinical Development
    • 16.5.4. Safety and Efficacy
  • 16.6. Risuteganib: Allegro Ophthalmics
    • 16.6.1. Product Description
    • 16.6.2. Other Developmental Activities
    • 16.6.3. Clinical Development
    • 16.6.4. Safety and Efficacy
  • 16.7. Elamipretide: Stealth BioTherapeutics
    • 16.7.1. Product Description
    • 16.7.2. Other Developmental Activities
    • 16.7.3. Clinical Development
    • 16.7.4. Safety and Efficacy
  • 16.8. GT005: Gyroscope Therapeutics
    • 16.8.1. Product Description
    • 16.8.2. Other Developmental Activities
    • 16.8.3. Clinical Development
  • 16.9. CPCB-RPE1: Regenerative Patch Technologies
    • 16.9.1. Product Description
    • 16.9.2. Other Developmental Activities
    • 16.9.3. Clinical Development
    • 16.9.4. Safety and Efficacy
  • 16.10. RO7171009 (RG6147): Roche (Genentech)
    • 16.10.1. Product Description
    • 16.10.2. Other Developmental Activities
    • 16.10.3. Clinical Development
  • 16.11. IONIS-FB-LRx: Ionis Pharmaceuticals/Roche
    • 16.11.1. Product Description
    • 16.11.2. Other Developmental Activities
    • 16.11.3. Clinical Development
  • 16.12. OpRegen: CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)
    • 16.12.1. Product Description
    • 16.12.2. Other Developmental Activities
    • 16.12.3. Clinical Development
    • 16.12.4. Safety and Efficacy
  • 16.13. Palucorcel (CNTO 2476): Janssen Research & Development
    • 16.13.1. Product Description
    • 16.13.2. Other Developmental Activities
    • 16.13.3. Clinical Development
    • 16.13.4. Safety and Efficacy

17. Conjoint Analysis of Geographic Atrophy (GA)

18. Geographic Atrophy (GA): Seven Major Market Analysis

  • 18.1. Key Findings
  • 18.2. Market Outlook: 7MM

19. 7MM Market Size

  • 19.1. Total Market Size of Geographic Atrophy in the 7MM
  • 19.2. Total Market size of Geographic Atrophy by Therapies in the 7MM
  • 19.3. United States Market Size
    • 19.3.1. Total Market size of Geographic Atrophy in the United States
  • 19.4. EU-5 Market Size
    • 19.4.1. Germany Market Size
    • 19.4.2. France Market Size
    • 19.4.3. Italy Market Size
    • 19.4.4. Spain Market Size
    • 19.4.5. United Kingdom Market Size
  • 19.5. Japan Market Size
    • 19.5.1. Total Market size of Geographic Atrophy in Japan

20. Market Access and Reimbursement of Geographic Atrophy (GA) Therapies

  • 20.1. Issues Associated with Access and Reimbursement of Gene Therapies
  • 20.2. Access and Reimbursement of Wet AMD Therapies

21. Market Drivers of GA

22. Market Barriers of GA

23. Appendix

  • 23.1. Bibliography
  • 23.2. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List of Tables:

  • Table 1: Summary of GA Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: The four-stage classification of AMD from the Age-Related Eye Disease Study (AREDS)
  • Table 3: AREDS Risk Factor Scoring System
  • Table 4: Total Prevalent Cases of Geographic Atrophy in the 7MM (2017-2030)
  • Table 5: Total Diagnosed cases of Geographic Atrophy in the 7MM (2017-2030)
  • Table 6: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the 7MM (2017-2030)
  • Table 7: Total Geographic Atrophy Cases by Visual Impairment in the 7MM (2017-2030)
  • Table 8: Total Treated cases of Geographic Atrophy in the 7MM (2017-2030)
  • Table 9: Total Prevalent Cases of Geographic Atrophy in the United States (2017-2030)
  • Table 10: Total Diagnosed cases of Geographic Atrophy in the United States (2017-2030)
  • Table 11: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United States (2017-2030)
  • Table 12: Total Geographic Atrophy Cases by Visual Impairment in the US (2017-2030)
  • Table 13: Total Treated cases of Geographic Atrophy in the US (2017-2030)
  • Table 14: Total Prevalent Cases of Geographic Atrophy in Germany (2017-2030)
  • Table 15: Total Diagnosed cases of Geographic Atrophy in Germany (2017-2030)
  • Table 16: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Germany(2017-2030)
  • Table 17: Total Geographic Atrophy Cases by Visual Impairment in Germany (2017-2030)
  • Table 18: Total Treated cases of Geographic Atrophy in Germany (2017-2030)
  • Table 19: Total Prevalent Cases of Geographic Atrophy in France (2017-2030)
  • Table 20: Total Diagnosed cases of Geographic Atrophy in France (2017-2030)
  • Table 21: Total Diagnosed cases of Geographic Atrophy by Age Distribution in France (2017-2030)
  • Table 22: Total Geographic Atrophy Cases by Visual Impairment in France (2017-2030)
  • Table 23: Total Treated cases of Geographic Atrophy inFrance (2017-2030)
  • Table 24: Total Prevalent Cases of Geographic Atrophy in Italy (2017-2030)
  • Table 25: Total Diagnosed cases of Geographic Atrophy in Italy (2017-2030)
  • Table 26: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Italy (2017-2030)
  • Table 27: Total Geographic Atrophy Cases by Visual Impairment in Italy (2017-2030)
  • Table 28: Total Treated cases of Geographic Atrophy in Italy (2017-2030)
  • Table 29: Total Prevalent Cases of Geographic Atrophy in Spain (2017-2030)
  • Table 30: Total Diagnosed cases of Geographic Atrophy in Spain (2017-2030)
  • Table 31: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Spain (2017-2030)
  • Table 32: Total Geographic Atrophy Cases by Visual Impairment in Spain (2017-2030)
  • Table 33: Total Treated cases of Geographic Atrophy in Spain (2017-2030)
  • Table 34: TotalPrevalent Cases of Geographic Atrophy in the United Kingdom (2017-2030)
  • Table 35: Total Diagnosed cases of Geographic Atrophy in the United Kingdom (2017-2030)
  • Table 36: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United Kingdom (2017-2030)
  • Table 37: Total Geographic Atrophy Cases by Visual Impairment in UK (2017-2030)
  • Table 38: Total Treated cases of Geographic Atrophy in the UK (2017-2030)
  • Table 39: Total Prevalent Cases of Geographic Atrophy in Japan(2017-2030)
  • Table 40: Total Diagnosed cases of Geographic Atrophy in Japan(2017-2030)
  • Table 41: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Japan (2017-2030)
  • Table 42: Total Geographic Atrophy Cases by Visual Impairment in Japan (2017-2030)
  • Table 43: Total Treated cases of Geographic Atrophy in Japan (2017-2030)
  • Table 44: Emerging Drugs Key-cross of Geography Atrophy (GA)
  • Table 45: Pegcetacoplan (APL-2), Clinical Trial Description, 2020
  • Table 46: Zimura (avacincaptad pegol), Clinical Trial Description, 2020
  • Table 47: ALK-001, Clinical Trial Description, 2020
  • Table 48: HMR59 (AAVCAGsCD59), Clinical Trial Description, 2020
  • Table 49: Risuteganib, Clinical Trial Description, 2020
  • Table 50: Elamipretide, Clinical Trial Description, 2020
  • Table 51: GT005, Clinical Trial Description, 2020
  • Table 52: CPCB-RPE1, Clinical Trial Description, 2020
  • Table 53: RO7171009; Clinical Trial Description, 2020
  • Table 54: IONIS-FB-LRx, Clinical Trial Description, 2020
  • Table 55: OpRegen; Clinical Trial Description, 2020
  • Table 56: Palucorcel (CNTO 2476); Clinical Trial Description, 2020
  • Table 57: Clinical Trials of Lampalizumab for GA
  • Table 58: 7MM Market Size of GA in USD Million (2017-2030)
  • Table 59: 7MM Market Size of GA by Therapies, in USD Million (2017-2030)
  • Table 60: United States Market Size of GA, in USD Million (2017-2030)
  • Table 61: United States Market Size of GA by Therapies, in USD Million (2017-2030)
  • Table 62: Germany, Market Size of GA, in USD Million (2017-2030)
  • Table 63: Germany Market Size of GA by Therapies, in USD Million (2017-2030)
  • Table 64: France, Market Size of GA, in USD Million (2017-2030)
  • Table 65: France Market Size of GA by Therapies, in USD Million (2017-2030)
  • Table 66: Italy, Market Size of GA, in USD Million (2017-2030)
  • Table 67: Italy Market Size of GA by Therapies, in USD Million (2017-2030)
  • Table 68: Spain, Market Size of GA, in USD Million (2017-2030)
  • Table 69: Spain Market Size of GA by Therapies, in USD Million (2017-2030)
  • Table 70: United Kingdom, Market Size of GA, in USD Million (2017-2030)
  • Table 71: United Kingdom Market Size of GA by Therapies, in USD Million (2017-2030)
  • Table 72: Japan, Market Size of GA, in USD Million (2017-2030)

List of Figures:

  • Figure 1: Geographic Atrophy (GA) SWOT Analysis
  • Figure 2: Dry AMD and Wet AMD
  • Figure 3: AREDS Risk Factor Scoring System
  • Figure 4: Stages of AMD
  • Figure 5: Signs and Symptoms of GA
  • Figure 6: Risk Factors of GA
  • Figure 7: Impact of GA progression on patient vision
  • Figure 8: Pathophysiology of GA
  • Figure 9: Classical, Lectin, and Alternative Complement Cascade-mediated Pathway
  • Figure 10: Complement Cascade-mediated Pathway
  • Figure 11: Assessment of GA
  • Figure 12: Characteristics of GA across different imaging technique
  • Figure 13: Progression of GA illustrated with high-resolution SD-OCT over a period of 14 months
  • Figure 14: Progression of GA illustrated by FAF imaging and GA quantification over time
  • Figure 15: Semi-automated quantification of GA by means of image analysis software (Region-Finder)
  • Figure 16: Total Prevalent Cases of Geographic Atrophy in the 7MM (2017-2030)
  • Figure 17: Total Diagnosed cases of Geographic Atrophy in the 7MM (2017-2030)
  • Figure 18: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the 7MM (2017-2030)
  • Figure 19: Total Geographic Atrophy Cases by Visual Impairment in the 7MM (2017-2030)
  • Figure 20: Treated cases of Geographic Atrophy in the 7MM (2017-2030)
  • Figure 21: Total Prevalent Cases of Geographic Atrophy in the United States (2017-2030)
  • Figure 22: Total Diagnosed cases of Geographic Atrophy in the United States(2017-2030)
  • Figure 23: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United States (2017-2030)
  • Figure 24: Total Geographic Atrophy Cases by Visual Impairment in the US (2017-2030)
  • Figure 25: Treated cases of Geographic Atrophy in the United States (2017-2030)
  • Figure 26: Total Prevalent Cases of Geographic Atrophy in Germany (2017-2030)
  • Figure 27: Total Diagnosed cases of Geographic Atrophy in Germany (2017-2030)
  • Figure 28: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Germany(2017-2030)
  • Figure 29: Total Geographic Atrophy Cases by Visual Impairment in Germany (2017-2030)
  • Figure 30: Treated cases of Geographic Atrophy in Germany (2017-2030)
  • Figure 31: Total Prevalent Cases of Geographic Atrophy in France (2017-2030)
  • Figure 32: Total Diagnosed cases of Geographic Atrophy in France(2017-2030)
  • Figure 33: Total Diagnosed cases of Geographic Atrophy by Age Distribution in France (2017-2030)
  • Figure 34: Total Geographic Atrophy Cases by Visual Impairment in France (2017-2030)
  • Figure 35: Treated cases of Geographic Atrophy in France (2017-2030)
  • Figure 36: Total Prevalent Cases of Geographic Atrophy in Italy (2017-2030)
  • Figure 37: Total Diagnosed cases of Geographic Atrophy in Italy (2017-2030)
  • Figure 38: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Italy (2017-2030)
  • Figure 39: Total Geographic Atrophy Cases by Visual Impairment in Italy (2017-2030)
  • Figure 40: Treated cases of Geographic Atrophy in Italy (2017-2030)
  • Figure 41: Total Prevalent Cases of Geographic Atrophy in Spain (2017-2030)
  • Figure 42: Total Diagnosed cases of Geographic Atrophy in Spain (2017-2030)
  • Figure 43: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Spain (2017-2030)
  • Figure 44: Total Geographic Atrophy Cases by Visual Impairment in Spain (2017-2030)
  • Figure 45: Treated cases of Geographic Atrophy in Spain (2017-2030)
  • Figure 46: Total Prevalent Cases of Geographic Atrophy in the United Kingdom (2017-2030)
  • Figure 47: Total Diagnosed cases of Geographic Atrophy in the United Kingdom(2017-2030)
  • Figure 48: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United Kingdom (2017-2030)
  • Figure 49: Total Geographic Atrophy Cases by Visual Impairment in the UK (2017-2030)
  • Figure 50: Treated cases of Geographic Atrophy in the United Kingdom (2017-2030)
  • Figure 51: Total Prevalent Cases of Geographic Atrophy in Japan (2017-2030)
  • Figure 52: Total Diagnosed cases of Geographic Atrophy in Japan(2017-2030)
  • Figure 53: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Japan (2017-2030)
  • Figure 54: Total Geographic Atrophy Cases by Visual Impairment in Japan (2017-2030)
  • Figure 55: Treated cases of Geographic Atrophy in Japan (2017-2030)
  • Figure 56: Treatment Algorithm of AMD
  • Figure 57: Unmet Needs of GA
  • Figure 58: Factors Which Can Influence Patients Quality of Life (QoL)
  • Figure 59: Market Size of GA in the 7MM Countries in USD Million (2017-2030)
  • Figure 60: Market Size of GA by Therapies in the 7MM, in USD Millions (2017-2030)
  • Figure 61: Market Size of GA in the United States, in USD Millions (2017-2030)
  • Figure 62: Market Size of GA by Therapies in the United States, in USD Millions (2017-2030)
  • Figure 63: Market Size of GA in Germany, in USD Millions (2017-2030)
  • Figure 64: Market Size of GA by Therapies in Germany, in USD Millions (2017-2030)
  • Figure 65: Market Size of GA in France, in USD Millions (2017-2030)
  • Figure 66: Market Size of GA by Therapies in France, in USD Millions (2017-2030)
  • Figure 67: Market Size of GA in Italy, in USD Millions (2017-2030)
  • Figure 68: Market Size of GA by Therapies in Italy, in USD Millions (2017-2030)
  • Figure 69: Market Size of GA in Spain, in USD Millions (2017-2030)
  • Figure 70: Market Size of GA by Therapies in Spain, in USD Millions (2017-2030)
  • Figure 71: Market Size of GA in the United Kingdom, in USD Millions (2017-2030)
  • Figure 72: Market Size of GA by Therapies in the United Kingdom, in USD Millions (2017-2030)
  • Figure 73: Market Size of GA in Japan, in USD Millions (2017-2030)
  • Figure 74: Market Drivers
  • Figure 75: Market Barriers